Peptide Initiative
Back to Lixisenatide

Clinical trials

Every registered trial of Lixisenatide

61 studies, 1 still enrolling.

Plain-Language Summary

Plain-language reading of the public trial registries.

In short

  • Lixisenatide has a real but limited body of human research.
  • 61 registered studies in total.
  • 1 is still enrolling people, so this is active research, not just history.

What kind of research

  • 55 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
  • About 21,458 people took part in those.
  • A further 6 studies only looked at records of people already taking it. These are counted separately because nobody was given the peptide for the study, so they cannot prove cause and effect.

A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.

Filter

Showing 61 of 61 trials for Lixisenatide.

  • NCT07188545 Active Not Recruiting23,280,000 enrolled2025

    Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

    Ohio State University

    Cardiovascular Kidney Metabolic Syndrome

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07117240 Phase 4Enrolling By Invitation100 enrolled2025

    Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes

    Medical University of Warsaw

    Steroid-Induced Diabetes · Steroid-Induced Hyperglycemia · Diabetes

  • NCT06449235 Phase 4Unknown938 enrolled2024

    Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

    Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders

    Type2diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT05804513 Phase 4Unknown10 enrolled2023

    The Effect of Lixisenatide on the Effect of Pituitary Hormones

    University of Tartu

    Healthy · Type 1 Diabetes

  • NCT05136287 Completed140 enrolled2022

    SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

    Jose Seijas Amigo

    Weight Loss · Diabetes Mellitus, Type 2 · Quality of Life · Safety Issues

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT05114590 Phase 4Completed124 enrolled2022

    Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT05220917 Active Not Recruiting781,430 enrolled2021

    Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

    Brigham and Women's Hospital

    Cardiovascular Events · Type2 Diabetes · Renal Disease

  • NCT03798054 Phase 3Completed878 enrolled2019

    Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT03959865 Unknown6,000 enrolled2018

    GLP-1 REceptor Agonists and Real World EvIdeNce

    University of Padova

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT03439943 Phase 2Completed156 enrolled2018

    Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease

    University Hospital, Toulouse

    Parkinson Disease

  • NCT03492580 Completed714,582 enrolled2018

    A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

    Janssen Research & Development, LLC

    Diabetes Mellitus, Type 2 · Cardiovascular Diseases

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT03434119 Phase 3Terminated241 enrolled2018

    Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT03130426 Phase 3Completed161 enrolled2017

    Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

    Population Health Research Institute

    Type 2 Diabetes Mellitus

  • NCT02803918 Phase 1Completed23 enrolled2017

    A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT02941367 Phase 4Completed184 enrolled2017

    Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan

    Sanofi

    Diabetes Mellitus, Type 2

  • Lixisenatide arterial stiffness trial (LAST)

    King’s College London and Guy’s and St Thomas’ NHS Foundation Trust

    Diabetes mellitus

  • NCT02767596 Phase 4Terminated2 enrolled2016

    Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog

    Laniado Hospital

    Diabetes Mellitus Type 2

  • NCT02787551 Phase 3Completed514 enrolled2016

    Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT02749890 Phase 3Completed321 enrolled2016

    Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT02745470 Completed30 enrolled2016

    Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain

    Seoul National University Hospital

    Diabetes Mellitus

  • NCT02640118 Completed24 enrolled2015

    The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects

    University Hospital, Gentofte, Copenhagen

    Diabetes After Total Pancreatectomy

  • NCT02231658 Phase 1Terminated109 enrolled2015

    Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

    Profil Institut für Stoffwechselforschung GmbH

    Diabetes Mellitus

  • NCT02274740 Phase 2Terminated2 enrolled2015

    Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

    Sanofi

    Type II Diabetes Mellitus

  • NCT02168491 Phase 3Completed10 enrolled2014

    Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin

    Medical University of Vienna

    Type 2 Diabetes Mellitus

  • NCT02244164 Terminated5 enrolled2014

    Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

    Erasme University Hospital

    Type 2 Diabetes · Incretinomimetics · Pancreas

  • NCT02501850 Phase 4Unknown40 enrolled2014

    The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)

    Hospital Universitari Vall d'Hebron Research Institute

    Diabetes Mellitus Type 2

  • NCT02276196 Phase 4Completed40 enrolled2014

    Effect of LIXIsenatide on the Renal System

    Amsterdam UMC, location VUmc

    Diabetic Kidney Disease · Diabetic Nephropathy · Diabetes Mellitus · Glucagon-Like Peptide 1

  • NCT02200991 Phase 4Completed136 enrolled2014

    Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

    Sanofi

    Type 2 Diabetes Mellitus

  • The effect of lixisenatide in type 1 diabetes

    University of Oxford (UK)

    Topic: Diabetes; Subtopic: Type 1 ; Disease: Diabetic Control

  • NCT04184947 Completed10,000 enrolled2014

    Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

    University of Padova

    Type 2 Diabetes

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT02058147 Phase 3Completed1,170 enrolled2014

    Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

    Sanofi

    Type 2 Diabetes

  • NCT02049034 Phase 4Completed8 enrolled2014

    Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes

    University of Surrey

    Type 2 Diabetes

  • NCT02020629 Phase 4Completed18 enrolled2013

    Study on Lixisenatide and Counterregulation to Hypoglycemia

    Lund University

    Type 2 Diabetes

  • NCT01960179 Phase 3Completed361 enrolled2013

    Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT02308254 Phase 1/2Unknown30 enrolled2013

    Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People

    Royal Adelaide Hospital

    Diabetes Mellitus · Gastroparesis

  • NCT01973231 Phase 4Completed404 enrolled2013

    Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

    Novo Nordisk A/S

    Diabetes · Diabetes Mellitus, Type 2

  • NCT01940965 Phase 3Completed294 enrolled2013

    Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT01798706 Phase 3Completed350 enrolled2013

    Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

    Sanofi

    Type 2 Diabetes

  • NCT01768559 Phase 3Completed894 enrolled2013

    Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

    Sanofi

    Type 2 Diabetes

  • NCT01632163 Phase 3Completed447 enrolled2012

    Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT01572649 Phase 1Completed24 enrolled2012

    Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT01596504 Phase 2Completed142 enrolled2012

    Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT01517412 Phase 3Completed451 enrolled2012

    Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT01476475 Phase 2Completed323 enrolled2011

    Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT01175473 Phase 2Completed148 enrolled2010

    Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT01169779 Phase 3Completed391 enrolled2010

    Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT01146678 Phase 1Completed22 enrolled2010

    Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1

    Sanofi

    Type 1 Diabetes Mellitus

  • NCT01147250 Phase 3Completed6,068 enrolled2010

    Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

    Sanofi

    Acute Coronary Syndrome

  • NCT00975286 Phase 3Completed446 enrolled2009

    24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT00976937 Phase 3Completed319 enrolled2009

    24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

    Sanofi

    Type 2 Diabetes Mellitus

  • NCT00931372 Phase 1Completed22 enrolled2009

    Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2

    Sanofi

    Diabetes Mellitus, Type 2

  • NCT00905255 Phase 3Completed69 enrolled2009

    GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)

    Sanofi

    Diabetes Mellitus, Type 2

  • NCT00866658 Phase 3Completed311 enrolled2009

    GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)

    Sanofi

    Diabetes Mellitus, Type 2

  • NCT00763451 Phase 3Completed484 enrolled2008

    GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

    Sanofi

    Diabetes Mellitus, Type 2

  • NCT00763815 Phase 3Completed484 enrolled2008

    GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone

    Sanofi

    Diabetes Mellitus Type 2

  • NCT00713830 Phase 3Completed859 enrolled2008

    GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea

    Sanofi

    Diabetes Mellitus, Type 2

  • NCT00715624 Phase 3Completed496 enrolled2008

    GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

    Sanofi

    Diabetes Mellitus, Type 2

  • NCT00712673 Phase 3Completed680 enrolled2008

    GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

    Sanofi

    Diabetes Mellitus, Type 2

  • NCT00707031 Phase 3Completed639 enrolled2008

    GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

    Sanofi

    Diabetes Mellitus, Type 2

  • NCT00688701 Phase 3Completed361 enrolled2008

    GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy

    Sanofi

    Diabetes Mellitus, Type 2

  • NCT00299871 Phase 2Completed542 enrolled2006

    Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus

    Sanofi

    Type 2 Diabetes

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Lixisenatide is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.